

Varicose Veins Guideline Development Group Meeting (GDG) 7

Date and Time: **Wednesday 11th July 2012 (10:00–16:30)**

Minutes: *Confirmed*

Place: *Boardroom, National Clinical Guideline Centre (NCGC), 180 Great Portland Street, London W1W 5QZ*

GDG Present: *(All present for notes 1–9 except where stated)*

Dr. Mustapha Azzam (MA)
Dr. Jocelyn Brookes (JB) (Present for notes 3-9)
Prof. Andrew Bradbury (AB)
Mrs. Joyce Calam (JC)
Mr. David Evans (DE)
Mr. Nick Hickey (NH)
Mr. Keith Poskitt (KP)
Mrs. Hazel Trender (HT)
Dr. Mark Vaughan (MV)

In attendance: *(All present for notes 1–9 except where stated)*

Expert Advisors: Ms. Jenny Greenfield (JG)

NICE Staff Ms. Caroline Keir (CK)

NCGC Staff: Mrs. Karen Head (KH)
Dr Kate Kelley (KK) (Chair)
Ms. Grace Marsden (GM)
Dr Mark Perry (MP)
Mr. David Wonderling (DW) (Present for notes 1-2)

Apologies Prof. Alun Davies (Chair) (AD)

Minutes

1. Welcome

KK welcomed the group to the sixth Varicose Veins Guideline Development Group Meeting (GDG6). It was noted that AD had sent apologies for absence.

KK invited everyone to declare their interests. AB declared a new personal non-pecuniary interest he had attended a meal with representatives from STD pharmaceuticals who make one of the components used in foam sclerotherapy.

KP declared a new specific non-personal pecuniary interest; his registrar had been funded by STD pharmaceuticals to present research at the European Venous Forum in Florence.

MA declared a new personal non-pecuniary interest; he has been involved in setting up GEKO stimulation device for the prevention of DVT.

No actions were taken following these declarations and none of the GDG members withdrew during discussion. There were no changes to any of the other GDG members' and NCGC staff's DOIs since the last meeting.

The minutes of GDG 6 were agreed as an accurate reflection of the meeting, there were no matters arising.

2. Health Economic Modelling

Members of the NCGC Technical Team presented the proposed economic model structure and data inputs for review. The GDG discussed the structure of the model and made modifications to further define and improve it. The GDG agreed the data inputs to the model.

3. Review question – In people with leg varicose veins at any CEAP class which signs, symptoms and/or patient characteristics are associated with disease progression to a more severe CEAP class?

Members of the NCGC Technical Team presented the clinical evidence for the above review question to the GDG. The GDG discussed the evidence presented.

4. Review questions - In people with leg varicose veins are there any factors (clinical signs and symptoms or patient reported outcomes) that would predict increased benefits or harms from varicose veins interventional treatments?

Members of the NCGC Technical Team presented the clinical evidence for the above review question to the GDG. The GDG discussed the evidence presented.

5. Clinical Question –Who to refer to a specialist?

The GDG discussed how the evidence presented in agenda items 3 and 4 above could be used to help develop recommendations.

6. Research Recommendations

Members of the NCGC Technical Team presented about the development of research recommendations. The GDG discussed options for potential research recommendations. Further discussion and voting needs to take place.

7. Follow up of outstanding actions

The GDG discussed areas not yet completed. They agreed a way forward for each of the topics.

8. Review of Guideline Progress

Members of the NCGC Technical team presented on overview of project progress.

9. Any other business and summary of next steps

No items of additional business were raised.

Date, time and venue of the next meeting

Wed October 3rd (10:00–16:30); Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ